Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.78 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.78 |
| ▸ | PIN1 | Q13526 | 6/20 | 0.64 |
| ▸ | CTSK | P43235 | 5/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | ICMT | O60725 | 1/20 | 0.54 |
| ▸ | GRN | P28799 | 1/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704949 | 1.00 | TAS1R3 (0.78) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL14362858 | 0.90 | TAS1R3 (0.78) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL7241995 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL10226447 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL4192862 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL6660145 | 0.88 | TAS1R3 (0.64) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL3913711 | 0.87 | PIN1 (0.64) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL14605678 | 0.87 | TAS1R3 (0.70) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL4144456 | 0.83 | TAS1R3 (0.65) | TAS1R3TAS1R1PIN1CTSKCTSB | |
| SCHEMBL5434145 | 0.83 | TAS1R3 (0.65) | TAS1R3TAS1R1PIN1CTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003846-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-11-13 | — | — | EP | claimed |
| US-20020013360-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-01-31 | — | — | US | claimed |
| EP-1003846-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1998050533-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-20100227856-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227856-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227856-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| EP-1796793-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1796677-A4 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2006029209-A2 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006029154-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-6566373-B2 | For therapy of osteoporosis, periodontitis, and arthritis | SMITHKLINE BEECHAM CORPORATION | 2003-05-20 | — | — | US | disclosed |
| EP-1003846-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020013360-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-01-31 | — | — | US | disclosed |
| EP-1003846-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998050533-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013360-A1 | Protease inhibitors | CTSK, CTSV, CTSS | TAS1R3 3510/4885TAS1R1 4032/4885PIN1 207/4885 |
| US-20100227856-A1 | NOVEL COMPOUNDS | TRPV4, TRPV1, TRPA1 | TAS1R3 314/4885TAS1R1 233/4885PIN1 1662/4885 |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TAS1R3 513/4885TAS1R1 487/4885PIN1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.